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Abstract: OBJECTIVES: To determine the impact of pretreatment low-abundance HIV-1 drug-resistant
variants (LA-DRVs) on virological failure (VF) among HIV-1/TB-co-infected individuals treated with
NNRTI first-line ART. METHODS: We conducted a case-control study of 170 adults with HIV-1/TB
co-infection. Cases had at least one viral load (VL) ฀1000 RNA copies/mL after ฀6 months on NNRTI-
based ART, and controls had sustained VLs <1000 copies/mL. We sequenced plasma viruses by Sanger
and MiSeq next-generation sequencing (NGS). We assessed drug resistance mutations (DRMs) using
the Stanford drug resistance database, and analysed NGS data for DRMs at ฀20%, 10%, 5% and 2%
thresholds. We assessed the effect of pretreatment drug resistance (PDR) on VF. RESULTS: We analysed
sequences from 45 cases and 125 controls. Overall prevalence of PDR detected at a ฀20% threshold was
4.7% (8/170) and was higher in cases than in controls (8.9% versus 3.2%), P = 0.210. Participants with
PDR at ฀20% had almost 4-fold higher odds of VF (adjusted OR 3.7, 95% CI 0.8-18.3) compared with those
without, P = 0.104. PDR prevalence increased to 18.2% (31/170) when LA-DRVs at ฀2% were included.
Participants with pretreatment LA-DRVs only had 1.6-fold higher odds of VF (adjusted OR 1.6, 95% CI
0.6-4.3) compared with those without, P = 0.398. CONCLUSIONS: Pretreatment DRMs and LA-DRVs
increased the odds of developing VF on NNRTI-based ART, although without statistical significance.
NGS increased detection of DRMs but provided no additional benefit in identifying participants at risk
of VF at lower thresholds. More studies assessing mutation thresholds predictive of VF are required to
inform use of NGS in treatment decisions.
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Objectives: To determine the impact of pretreatment low-abundance HIV-1 drug-resistant variants (LA-DRVs)
on virological failure (VF) among HIV-1/TB-co-infected individuals treatedwith NNRTI first-line ART.
Methods: We conducted a case–control study of 170 adults with HIV-1/TB co-infection. Cases had at least one
viral load (VL) 1000 RNA copies/mL after 6months on NNRTI-based ART, and controls had sustained VLs
<1000 copies/mL. We sequenced plasma viruses by Sanger and MiSeq next-generation sequencing (NGS). We
assessed drug resistancemutations (DRMs) using the Stanford drug resistance database, and analysedNGS data
for DRMs at 20%, 10%, 5% and 2% thresholds. We assessed the effect of pretreatment drug resistance (PDR)
on VF.
Results: Weanalysed sequences from45 cases and 125 controls. Overall prevalence of PDR detected at a20%
threshold was 4.7% (8/170) and was higher in cases than in controls (8.9% versus 3.2%), P=0.210. Participants
with PDR at20% had almost 4-fold higher odds of VF (adjusted OR 3.7, 95% CI 0.8–18.3) compared with those
without, P=0.104. PDR prevalence increased to 18.2% (31/170) when LA-DRVs at 2% were included.
Participants with pretreatment LA-DRVs only had 1.6-fold higher odds of VF (adjusted OR 1.6, 95% CI 0.6–4.3)
comparedwith thosewithout, P=0.398.
Conclusions: Pretreatment DRMs and LA-DRVs increased the odds of developing VF on NNRTI-based ART, al-
though without statistical significance. NGS increased detection of DRMs but provided no additional benefit in
identifying participants at risk of VF at lower thresholds. More studies assessingmutation thresholds predictive of
VF are required to inform use of NGS in treatment decisions.
Introduction
The success of scaling-up ART is greatly threatened by the emer-
gence and transmission of HIV drug resistance (HIVDR). HIVDR
that occurs in individuals who have not yet initiated ART, or who
have prior ART use and are re-initiating first-line treatment, is
known as pretreatment drug resistance (PDR).1,2 PDR is associated
with poor ART outcomes,3,4 and there is strong evidence suggest-
ing a substantial increase in levels of PDR in southern Africa,
the region with the greatest HIV epidemic.2,5,6 With evidence of
increasing PDR, the WHO now recommends modifying the stand-
ard first-line ART regimen or introducing pretreatment HIVDR test-
ingwhenNNRTI-PDR levels reach10%.1
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Changing the standard first-line ART regimen offers a more
feasible alternative option to pretreatment HIVDR testing. The
WHO recommends use of dolutegravir, an integrase strand trans-
fer inhibitor (INSTI), that is cheaper and better tolerated compared
with current NNRTIs.7–9 Despite this recommendation, concerns
over use of dolutegravir among specific subpopulations remain.
This includes women of child-bearing age, due to potential for
neural tube birth defects occurring when dolutegravir is used at
the time of conception.10–12 In addition, concerns also exist
regarding co-administration of dolutegravir and TB treatment
among HIV-1/TB-co-infected people, specifically from drug–drug
interactions with rifampicin,9 and in patients who do not tolerate
dolutegravir.13 This highlights potential for the continued use of
NNRTIs, and the relevance of assessing the impact of NNRTI resist-
ancemutations onART.
Sanger sequencing has been the conventionalmethod used for
detecting HIV drug resistance mutations (DRMs). Sanger sequenc-
ing is relatively expensive, and does not reliably detect mutations
that are not well represented, i.e. occurring at <20% of the viral
population.14,15 With advances in technology, next-generation
sequencing (NGS) is becoming more popular and likely to replace
Sanger sequencing in routine laboratory workflows.14 NGS allows
for multiplexing of samples, thereby reducing the cost of HIVDR
testing. Furthermore, NGS has the ability to detect low-abundance
drug-resistant variants (LA-DRVs), i.e.mutations occurring in <20%
of the viral population.14
There is evidence suggesting that NNRTI-PDR detected by
Sanger sequencing results in poor ART outcomes,16–18 but there
remains limited knowledge around the impact of LA-DRVs on
treatment outcomes, and at different mutation frequencies.
We sought to determine the impact of pretreatment LA-DRVs on




This research study was approved by the Biomedical Research Ethics
Committee of the University of KwaZulu-Natal (reference number: BF340/
17). Ethics approvals were also obtained from the Biomedical Research
Ethics Committee of the University of KwaZulu-Natal (reference numbers:
E107/05andBF051/09; Clinicaltrials.gov numberNCT 01539005) for studies
from which samples were obtained, and participants gave informed con-
sent for sample storage and re-use.
Study design and study population
This was a nested case–control study aimed at determining the impact of
pretreatment LA-DRVs on NNRTI-based ART outcomes. We defined VF as
having at least one viral load (VL) 1000 HIV-1 RNA copies/mL in plasma
after6months on NNRTI-based ART. De-identified remnant plasma sam-
ples from HIV-1/TB-co-infected adults (18years) were obtained from the
Starting Antiretroviral therapy at three Points in Tuberculosis (SAPiT) trial,
and from a subsequent study known as the TB Recurrence upon Treatment
with HAART (TRuTH).
The SAPiT trial was an open-label, randomized, controlled trial
conducted by the Centre for AIDS Programme Research in Africa (CAPRISA)
between June 2005 and July 2008, at the eThekwini Clinical Research Site
(ECRS) in Durban, South Africa. The study investigated the effect of ART
started during TB treatment (in two integrated-therapy groups) or after
completion of TB treatment (in one sequential-therapy group) onmortality.
The majority of participants received a once-daily regimen of efavirenz,
lamivudine and didanosine (EFV/3TC/ddI) at ART initiation, but drug
switches were allowed during the study. VLs were measured at the time of
screening, at randomization and every 6months thereafter. SAPiT study
participants were enrolled into the TRuTH study, a prospective cohort study
conducted between 2009 and 2013. The study aimed to assess TB recur-
rence among participants who were either cured or had successfully com-
pleted their TB treatment after 24months follow-up in SAPiT. Details of the
SAPiT and TRuTH studies have been publishedpreviously.19–21
In this analysis, we defined cases as participants with at least one VL
1000 copies/mL after 6months of initiating an NNRTI-based ART. We
defined controls as participants who had sustained virological suppression
(VL <1000 copies/mL) after at least 6months on ART (SAPiT ± TRuTH),
and maintained viral suppression throughout the study follow-up period
(5–6years). Pre-ART samples from cases and controls were included in a
1:2 case:control ratio. A simple random sampling strategy was used to se-
lect unmatched controls. If plasma sampleswere not available for cases at
their first high VL, we accessed a subsequent sample based on availability
of remnant plasma. We excluded participants who had switched from an
NNRTI-based regimen at the time of ART failure.
Laboratory methods
We retrieved plasmasampleswith VLs1000 copies/mL froma#80C bio-
repository and thawed them to room temperature prior to viral RNA extrac-
tion. For each sample, we centrifuged 500lL of plasma at 23000g for 1h
at 4C to pellet the virus. We extracted viral RNA from 200lL of pelleted
plasma using a NucliSens EasyMAG HIV-1 (bioMérieux, Craponne, France)
extraction system, and amplified the protease and reverse transcriptase
genes using Southern African Treatment Resistance Network custom pri-
mers, as described previously.22 We purified successfully amplified PCR
products using a QIAquick PCR purification kit (Qiagen, Hilden, Germany),
according to the manufacturer’s instructions. To limit sample variability in
the final sequencing product, we aliquotted purified PCR products of each
sample for Sanger sequencing andNGS.
Sanger sequencing
In preparation for capillary electrophoresis, weperformed sequencing reac-
tions using a BigDye Terminator v3.1 kit (Applied Biosystems, Foster City, CA,
USA), and sequencing reaction purifications using a BigDye XTerminator
v3.1 purification kit (Applied Biosystems), according to the manufacturer’s
instructions.We performed capillary electrophoresis on an ABI 3730 genet-
ic analyser and assessed the quality of sequences using Geneious software
v8.1.9 (Biomatters Ltd, New Zealand).23 We excluded sequences with in-
complete reverse transcriptase (codons 1–254) genes, and detected DRMs
using the Stanford University HIV drug resistance database (version 8.6).24
Next-generation sequencing
For NGS, we determined PCR product concentrations using aQubit 3.0 fluor-
imeter (Life Technologies, Malaysia), diluted amplicons to 0.2ng/lL and
performed library preparation using the Nextera-XT DNA Library
Preparation kit andNextera Index kit (Illumina, SanDiego, CA, USA), accord-
ing to the manufacturer’s instructions. In summary, library preparation
involved kit-based enzymatic fragmentation of DNA, dual indexing of frag-
mented DNA and bead-based purification of amplicons using AMPure
beads (Beckman Coulter, Brea, CA, USA). We performed quality control
steps using the LabChip GX Touch (PerkinElmer, Hopkinton, MA, USA) to
determine the amplicon size, and used the Qubit 3.0 fluorometer (Life
Technologies, Malaysia) to determine library concentrations. We normal-
ized each sample library to 4nM concentration, pooled the normalized
libraries and diluted them to a final concentration of 10 pM. We spiked the
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10 pM library with 5% PhiX control, and sequenced it on an Illumina MiSeq
platformusing theMiSeqNano Reagent Kit v2 (500 cycles).
For paired-end sequencing analysis, we used Genome Detective, a web-
based tool for analysis of molecular sequence data (https://www.genome
detective.com).25 In summary, the software used Trimmomatic for quality
control in filtering sequences, for adaptor trimming and for checking for
external contamination. It generated gene coverage plots and mapped
them to a default HIV-1 subtype C reference sequence in Genome
Detective.Weexcluded sequenceswith <100% depth of coverage or having
incomplete reverse transcriptase (codons 1–254) genes. We aligned the
sequences to an annotated HIV-1C reference sequence, and analysed for
LA-DRVs inGeneious software v8.1.9 (Biomatters Ltd, NewZealand).23
Drug resistance analysis
We determined both Sanger sequencing and NGS DRMs based on the
Stanford University HIV drug resistance database (version 8.6).24 We esti-
mated HIVDR prevalence at 20%, 10%, 5% and 2% thresholds, and
defined drug resistance as having an NRTI resistancemutation or an NNRTI
resistance mutation. We excluded individuals who did not have both an
NGS and Sanger sequence either at the pre-ART timepoint or at VF. We
excluded PI resistance mutations from our analysis, as none of the partici-
pants selectedhad initiated PI-basedART regimen.
Data analysis
We used STATA v13 (StataCorp, College Station, TX, USA) for statistical
analysis. We used the Fisher’s exact test and Wilcoxon rank-sum test (for
categorical and continuous variables, respectively) to compare baseline
demographics (i.e. sex and age) and clinical characteristics (CD4 count, VL,
months onART and SAPiT randomization arm) between cases and controls.
We analysed the effect of PDR majority mutations on ART. To determine
the impact of pretreatment LA-DRVs on VF, we excluded PDR majority
mutations (i.e.mutations at20% threshold) from the analysis.We further
excluded thymidine analoguemutations (TAMs) D67NGE and K219NE, that
do not confer any resistance to didanosine. We used univariable andmulti-
variable logistic regression to assess the association between pretreatment
LA-DRVs and VF. Themodelwas adjusted for age, gender, CD4 count at ART
initiation, VL at ART initiation, and randomization. We did not adjust for
time on ART and TB medications, as controls were only sampled prior to




We identified 99/642 cases with at least one VL1000 copies/mL
after receiving ART for at least 6months, with approximately 50%
(50/99) of the cases having two consecutive VLs 1000
copies/mL. From a total of 543 participants with sustained viro-
logical suppression, we selected 198 controls, giving a total of 297
participants (i.e. 99 cases and 198 controls). Of the 297 partici-
pants, 207 (69 cases and 138 controls) had appropriate samples
available for testing. The median duration on ART for the 69 cases
was 5 years (IQR 4.5–5.6) and the median duration on ART for the
138 controls was 6 years (IQR 5.0–6.3) (Figure S1, available as
Supplementary data at JAC Online). We obtained complete NGS
and Sanger sequence pairs for 170 participants (45 cases and 125
controls) (Figure1, Table S1). Thirty-two of the 45 (71%) cases
achieved viral suppression at subsequent points including those
who switched ART.
All except two participants (168/170) received EFV/3TC/ddI at
ART initiation. Of the two participants (i.e. controls), one received
efavirenz with zidovudine and lamivudine, and the other received
nevirapine with lamivudine and didanosine at ART initiation.
Table1 summarizes the demographic and clinical characteristics
of the participants included in the final analysis. We did not
observe any significant differences in demographic and clinical
characteristicswhen comparing cases and controls.
HIV-1 drug resistance data before ART initiation
Overall, of 170 pre-ART sequences, all were subtype C. Eight (4.7%)
had at least one DRM detected by Sanger sequencing and by NGS
at a 20% threshold (four cases and four controls). NGS at a
20% threshold (i.e. majority drug resistance) was completely
concordant with Sanger sequencing, so from this point onwards
we only refer to NGS data. Seven of the eight sequences revealed
single class resistance (two NRTI and five NNRTI), the other case




Participants with samples processed
n = 207
Participants with unsuccessful HIV
genotype
n = 37
(Cases, n = 24; Controls, n = 13)
Participants with samples not processed
n = 90
(Cases, n = 30; Controls, n = 60)
Failed amplification (22)
Incomplete sequences (15)
Samples unavailable in biorepository (83)









Figure 1. Summary flow chart of participants from selection to analysis.
aCases included all participants enrolled in the SAPiT trial that had viral
loads 1000 copies/mL after 6months on ART. bControls were ran-
domly selected from SAPiT trial participants to match cases at a 1:2
ratio.
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harboured both NRTI and NNRTI resistance. The most common
mutations (K103N and V108I) were detected in 3/8 pre-ART
sequences (Table S2). Table2 summarizes the pre-ART drug class
mutations observed by NGS at different mutation thresholds.
Figure 2 shows the prevalence of majority DRMs and LA-DRVs at
pre-ART, in cases and controls, respectively.
Impact of pretreatment majority DRMs and LA-DRVs
on VF
The overall prevalence of pretreatment majority DRMs was higher
in cases than in controls (8.9% versus 3.2%), P=0.210. Overall me-
dian time to VF among cases was 15.5months (IQR 9.2–29.2).
Caseswith PDR at a20% threshold had a shortermedian time to
VF (9.4months, IQR 8.4–14.7) compared with cases without PDR
mutations (16.3months, IQR 9.2–30.4), P=0.151. Participants
with pretreatment majority DRMs (i.e. at a 20% threshold) had
almost 4-fold higher odds of VF [adjusted OR (aOR) 3.7, 95% CI
0.8–18.3] compared with those without (P=0.104). PDR preva-
lence increased to 18.2% (31/170) when LA-DRVs at 2% were
included (24.4% among cases and 16.0% among controls),
P=0.260. Of the 170 pre-ART sequences, 23 (13.5%, 7 cases and
16 controls) had LA-DRVs only (i.e. mutations at 2% to <20%),
2 with dual class resistance and 21with single class resistance, i.e.
NRTI (15) andNNRTI (6) resistance. Participantswith pretreatment
LA-DRVs had 1.6-fold higher odds of VF (aOR 1.6, 95% CI 0.6–4.3)
compared with those without (P=0.398). The pre-ART LA-DRVs
were as follows: 10.0% (17/170) for NRTIs (6 cases and 11 con-
trols) and 4.7% (8/170) for NNRTIs (2 cases and 6 controls). The
most common pre-ART DRM was K65R, occurring in 6 of 170
(3.5%) sequences (Figure2a). The median frequency of K65R at
pre-ART was 2.8% (IQR 2.2–3.1), and it occurred as the only muta-
tion in five of the six sequences.
Twenty-eight of 31 (90%) participants harboured pretreatment
NRTI- and/or NNRTI-LA-DRVs that are associated with resistance
to the ART regimen the participants were taking. Of those, only








Female, n (%) 99 (58.2) 29 (64.4) 70 (56.0) 0.326
Age in years, median (IQR) 34 (29–40) 35 (27–39) 34 (29–41) 0.420
Viral load (log10 copies/mL), median (IQR)
a 5.3 (4.8–5.7) 5.2 (4.8–5.7) 5.3 (4.8–5.7) 0.496
CD4 count (cells/mm3), median (IQR) 141 (58–224) 107 (42–219) 150 (83–225) 0.148
Treatment armsb
early integrated, n (%) 50 (29.4) 12 (26.7) 38 (30.4)
late integrated, n (%) 65 (38.2) 17 (37.8) 48 (38.4)
sequential, n (%) 55 (32.4) 16 (35.6) 39 (31.2)
Baseline refers to time of enrolment in the SAPiT trial.
aOne case and two controls with missing viral loads prior to ART initiation.
bEarly integrated arm, ART initiated within a month of starting TB treatment; late integrated arm, ART initiated within a month of completing inten-
sive phase of TB treatment; sequential arm, ART initiated within a month of completing the continuation phase of TB treatment.
Table 2. Proportion of pre-ART NRTI and NNRTI resistance by NGSmutation thresholds
Detection threshold
Characteristics 2% 5% 10% 20%
Overall resistance (n=170)
Any resistance, n (%) 31 (18.2) 13 (7.7) 11 (6.5) 8 (4.7)
Any NRTI resistance, n (%) 19 (11.2) 6 (3.5) 5 (2.9) 2 (1.2)
Any NNRTI resistance, n (%) 15 (8.8) 8 (4.7) 7 (4.1) 7 (4.1)
Cases (n=45)
Any resistance, n (%) 11 (24.4) 7 (15.6) 7 (15.6) 4 (8.9)
Any NRTI resistance, n (%) 7 (15.6) 2 (4.4) 1 (2.2) 1 (2.2)
Any NNRTI resistance, n (%) 6 (13.3) 5 (11.1) 4 (8.9) 4 (8.9)
Controls (n=125)
Any resistance, n (%) 20 (16.0) 6 (4.8) 4 (3.2) 4 (3.2)
Any NRTI resistance, n (%) 12 (9.6) 4 (3.2) 4 (3.2) 1 (0.8)




three cases showed selection of LA-DRVs to majority DRMs at VF.
The LA-DRVs selected for were K65R, L74I and V106AI mutations.
The NNRTI mutation V106AI became a majority V106M mutation
at VF in two cases, whilst the NRTI mutation L74I became a
majority L74V mutation in one case, and the NRTI mutation K65R
becameamajority DRM in one case (Table S3). Despite K65Roccur-
ring as the most common DRM at pre-ART, the mutation was only
selected for in one of the three cases.
Drug resistance data at virological failure
At VF, 80.0% (36/45) had majority DRMs (i.e. a 20% threshold),
and the proportion increased to 84.4% (38/45) when LA-DRVs at
2%were included. Of the 36withmajority DRMs, 27 had dual class
resistance and 9 had single class NNRTI resistance. The most
commonmajority NNRTImutation at VF was V106MI, occurring in
48.9% (22/45) of sequences, whilst M184VI was the most com-
mon NRTI mutation, occurring in 46.7% (21/45) of sequences.
None of the baseline characteristics (i.e. sex, age, CD4 counts, VLs
and study arm)was associatedwith VF (Table S4).
Discussion
In this analysis, we observed an increase in odds of VF among indi-
viduals with either pre-ART majority DRMs or LA-DRVs compared
with those without, although without statistical significance. We
observed that lowering the mutation detection threshold
increased the detection of DRMs but had no additional benefit
in identifying participants at risk of VF. We also observed that
early versus delayed ART with rifampicin-based TB treatment did
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Figure 2. (a) Drug resistance mutations detected in cases with pre-ART resistance. (b) Drug resistance mutations detected in controls with pre-ART
resistance. Major mutations represent mutations detected at frequencies of 20% threshold, and minor variants represents mutations detected at
frequencies of between 2% and <20%.
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definition of VF as having at least one VL 1000 copies/mL after
6months on ART means that the proportions of DRMs reported
are likely not to be reflective of those observed in people with pro-
longed viraemia on ART. This is considering that some participants
might have suppressed their VL following intervention and there-
fore would not be ordinarily classified as VFs. Also, the lack of ART
adherence data in this analysis means that we could not rule out
poor ART adherence as a cause of VF amongst the cases.
A recent systematic review by the WHO HIVResNet working
group showed that the majority of published studies (14 of 25)
have reported no significant association between LA-DRVs and VF,
among individuals exposed to first-line NNRTI-based regimens.18
However, 11 of the 25 studies showeda higher risk of VFwhen indi-
viduals harbour NNRTI LA-DRVs prior to treatment initiation,18 sug-
gesting that LA-DRVs still play an important role in treatment
response. The ANRS 12249 trial showed that having dual class
resistance (NRTI and NNRTI) at 5% increased the time to viral
suppression by almost 12months (IQR 2.76–16.39) compared
with not having PDR (median 3.48months; IQR 2.79–5.78),26 an
outcome we could not determine in our study due to only three
participants having dual class pretreatment LA-DRVs. However,
despite the increased risk of VF with LA-DRVs at 5%, the ANRS
12249 trial further suggested that a combination of potent NRTI
drugs with an NNRTI, coupled with good ART adherence, could re-
sult in short-term virological suppression even in the presence of
pretreatment NNRTI DRMs.26
Controversy remains around the effect of pretreatment
LA-DRVs on ART, as shown previously in the OCTANE trials. The
OCTANE/A5208 trial 1,27 done among women that had prior
exposure to single dose nevirapine (sdNVP), suggested that pre-
treatment LA-DRVs have a significant impact on ART outcomes,
whilst the follow-upOCTANE trial 2 showedno such impact among
women without prior exposure to sdNVP.28 The contradiction sug-
gested that prior exposure to NNRTIs before ART initiation
increases the mutant population size that can be selected for on
NNRTI-based ART. This is supported by PDR data from a Kenyan
cohort study showing that the number of pretreatment NNRTI
mutations and their frequency (in a sample isolate) determine the
risk of treatment failure, with a greater risk among individuals on
nevirapine-based ART compared with efavirenz-based ART.29
Given that any history of previous prevention of mother-to-child
transmission (PMTCT) of HIV was not available, and noting the
demographic distribution of participants included, it is likely that
some women included in our analyses had undisclosed prior ART
exposure for PMTCT.
The differences observed in the impact of pretreatment
LA-DRVs on ART outcomes can be attributed to several factors. The
WHO HIVResNet working group identified factors such as: the
method of detecting HIVDR mutations; the analyses of mutations
affecting one or more drug classes; the inclusion in some cases of
majority DRMs; different mutation cut-off thresholds; variability in
the stage of PDR detection; and differences in the number of
individuals included in each study.18 Therefore, lower frequency
thresholds of mutations should be interpreted with caution.
A multicountry nested case–control study showed a reduction in
specificity from 98% (95% CI 95%–99%) at a 20% threshold, to
92% (95% CI 88%–95%) at a 1% threshold,30 suggesting that the
accuracy of resistance as a predictor of VF decreases with a
reduction in the detection threshold. Such reductions in specificity
could result in unnecessary modification of ART regimens, war-
ranting the need for careful consideration of the benefits and
shortcomings of detecting LA-DRVs for public health purposes.
Themost commonNNRTImutations at VF occurred at positions
where mutations are known to be highly selected for by efavirenz
(i.e. positions 103, 106, 188 and 190),24 suggesting adequate drug
pressure for the selection of NNRTI DRMs. However, of greater rele-
vance to the current ART programmes are NRTI resistance muta-
tions. As more countries (including South Africa) roll out
dolutegravir in combination with tenofovir and lamivudine (also
known as TLD), ensuring the potency of the NRTI drugs is impera-
tive to the success of the new ART regimen. The K65R mutation
which causes high levels of resistance to tenofovir and intermedi-
ate resistance to lamivudine24 is of greater concern in the TLD
regimen. We detected the K65R mutation at a frequency of only
2%–5% pre-ART, evolving to a majority DRM in only one out of the
three participants, and therefore we could not assess its impact on
VF, with didanosine treatment. However, continued monitoring
of NRTI resistance is warranted in order to avoid potential dolute-
gravir functional monotherapy due to pre-existing NRTI DRMs.
Moreover, despite dolutegravir replacing NNRTIs in first-line ART,
monitoring NNRTI resistance remains important in specific subpo-
pulations, such as women of child-bearing age, HIV-1/TB-treated
individuals and thosewhodonot tolerate dolutegravir.
The findings from this study should be interpreted with consid-
eration of the following limitations. Basing VF on only one VL result
is not conventional. However, 84% (38/45) of the cases in this
study already had majority DRMs, with over half of them having
dual class NRTI and NNRTI resistance at VF, suggesting the need
to consider early VLmonitoring and switching of ART regimens be-
fore the accumulation of DRMs.31 Secondly, about 43% (127/297)
of the selected participants ended up being excluded from the
analysis (Figure1) due to the unavailability of stored samples and
unsuccessful genotyping. However, there was no significant differ-
ence between the participants included and those excluded
among the cases (Table S1). Lastly, most participants in this study
initiated ART on didanosine, a drug that is not commonly used in
current regimens.
In conclusion, in a population of individuals treated for HIV-1/TB
initiated on NNRTI-based ART, we found that pretreatment
LA-DRVs increased the odds of VF, although without statistical
significance. Despite the ability of NGS to detect lower frequency
mutations, LA-DRVsmust be interpretedwith caution to avoidmis-
classification of people as being at risk of VF and hence unneces-
sary modification of ART regimens. More studies investigating the
impact of LA-DRVs on ART are required, including individuals with
different clinical characteristics, and considering variables such
as the time to VF due to outgrowth of LA-DRVs, the role of viral
mutational loads and specificmutation cut-off thresholds that can
inform use of NGS in guiding HIV treatment decisions at a public
health level.
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